UB389
TargetsER
IndicationsBreast cancer
ClinicalCN - Pre-IND
TherapeuticsOncology
ModalitiesSmall Molecule
Exclusive Summary
- • Utilizes a second-generation ER binder derived from the novel SERD Camizestrant and may demonstrate superior efficacy in both ESR1 wild-type and mutant HR+/HER2- breast cancer patients.
- • Better oral bioavailability compare with ARV-471
- • Comparable efficacy and safety profile to the SERD camizestrant at equivalent molar doses.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →